NeoGen Investors has filed a defamation suit against Hollywood, USA industrialist Burt Sugarman and his Giant Group, claiming they have slandered and defamed Joseph Pike, NeoGen's founder, to try to force him to give up the rights to the abortion pill mifepristone (also known as RU-486). Mr Pike holds US manufacturing and distribution rights to the product.
Giant further says it invested $6 million in the marketing effort. Last month, Giant Group subsidiary KCC Delaware sued Mr Pike and accused him of hiding his criminal past when he was negotiating the $6 million deal. NeoGen claims that the KCC suit has left Mr Pike and his family open to threats from antiabortion groups; its suit further states that Giant did not pay any money and that an exclusive agreement with NeoGen expired at the end of September. A Giant spokesman said that the money was not due until mifepristone was approved by the US Food and Drug Administration.
The nonprofit Population Council, to which mifepristone's developer Roussel Uclaf transferred US patent rights, has subleased its rights to several companies, including NeoGen. The Council, saying it would not have given NeoGen rights had it known that Mr Pike was disbarred in North Carolina in 1993 for forgery and fraud in a real estate deal, has asked for a court order to force Mr Pike to give up control of companies that make the pill in the USA. The Council says that this abortifacient has a possible $100 million market in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze